
Obalon Therapeutics, Inc. OBLN
Obalon Therapeutics, Inc. Gross Profit 2011-2026 | OBLN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Obalon Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 584 K | 331 K | 3.68 M | 5.08 M | 584 K | 1.54 M | 627 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.08 M | 331 K | 1.78 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 215.63 | -4.38 % | $ 15.2 B | ||
|
Profound Medical Corp.
PROF
|
4.38 M | $ 5.78 | 12.23 % | $ 180 M | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Quanterix Corporation
QTRX
|
65 M | $ 3.92 | 2.62 % | $ 167 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 9.54 | - | $ 735 M | ||
|
AVITA Medical
RCEL
|
58.8 M | $ 3.97 | 3.39 % | $ 111 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.33 | -1.48 % | $ 21.5 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
Sintx Technologies
SINT
|
461 K | $ 2.55 | -0.77 % | $ 7.07 M | ||
|
CONMED Corporation
CNMD
|
750 M | $ 36.9 | 0.86 % | $ 1.15 B | ||
|
Smith & Nephew plc
SNN
|
4.05 B | $ 32.43 | 0.82 % | $ 23.8 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
NanoVibronix
NAOV
|
1.51 M | - | - | $ 1.08 M | ||
|
Electromed
ELMD
|
50 M | $ 24.73 | 0.12 % | $ 209 M | ||
|
Sensus Healthcare
SRTS
|
11.9 M | $ 4.21 | 6.31 % | $ 68.7 M | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
Tactile Systems Technology
TCMD
|
250 M | $ 26.86 | -0.02 % | $ 614 M | ||
|
TELA Bio
TELA
|
40.1 M | $ 0.7 | -7.88 % | $ 16 M | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.67 | -3.33 % | $ 36.5 M | ||
|
Aethlon Medical
AEMD
|
1.36 M | $ 2.38 | 10.12 % | $ 3.71 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Tandem Diabetes Care
TNDM
|
167 M | $ 24.02 | -2.02 % | $ 1.63 B | ||
|
InspireMD
NSPR
|
2.65 M | $ 1.76 | -0.56 % | $ 113 M | ||
|
AdaptHealth Corp.
AHCO
|
89.3 M | $ 11.33 | -1.31 % | $ 1.53 B | ||
|
Penumbra
PEN
|
942 M | $ 336.05 | 0.54 % | $ 13.1 B | ||
|
Myomo
MYO
|
26.9 M | $ 0.69 | -0.33 % | $ 28.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
-10.6 M | $ 2.28 | -5.0 % | $ 134 M | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.7 | -5.37 % | $ 138 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 16.22 | 1.95 % | $ 381 M | ||
|
Outset Medical
OM
|
46.8 M | $ 3.49 | -1.27 % | $ 53.1 K | ||
|
Inspire Medical Systems
INSP
|
779 M | $ 51.29 | -1.52 % | $ 1.51 B | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.29 | -1.53 % | $ 52.5 M |